Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically ...

Explore a rare case of systemic mastocytosis in a young adult, highlighting its role in unexplained osteoporosis and the need ...

THB335 showed dose-dependent serum tryptase reductions from 13% to 84% at Day 15, supporting its advancement to Phase 2 in ...

James made a notable change in their assessment of Third Harmonic (NASDAQ:HLIT) Bio (NASDAQ:THRD), downgrading the biotechnology company's stock rating from Outperform to Market Perform. According to ...

Third Harmonic Bio (THRD) announced results from its Phase 1 single and multiple ascending dose clinical trial of THB335 in healthy volunteers.

A mild positive food effect was observed as well. Pharmacodynamics Dose-dependent reductions in serum tryptase, a biomarker of mast cell activation, were observed in the MAD cohorts, with mean ...

A new case report was published in Oncoscience's Volume 12 on February 4, 2025, titled “Breaking point: Systemic mastocytosis manifesting as severe osteoporosis.” ...

Blueprint Medicines' fourth-quarter earnings and sales miss estimates. Shares of the company decline following the ...

This report highlights the diagnostic challenges of SM, emphasize its underrecognized role in osteoporosis and fragility fractures, and advocates for ...

Blueprint Medicines Corporation ( NASDAQ: BPMC) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET ...